Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
An Observational Study of Efficacy and Safety of Modern Insulin in Diabetes Patients Switched From Anti-diabetic Treatment
- First Posted Date
- 2008-06-17
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5926
- Registration Number
- NCT00698269
- Locations
- 🇸🇦
Novo Nordisk Investigational Site, Riyadh, Saudi Arabia
Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2016-12-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 64
- Registration Number
- NCT00697320
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Mainz, Germany
Observational Study on the Weight Effect of Insulin Detemir (Levemir®) in Type 2 Diabetics
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2016-11-23
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 206
- Registration Number
- NCT00697450
- Locations
- 🇨🇿
Novo Nordisk Investigational Site, Prague, Czech Republic
An Observational Study of Type 2 Diabetes in Patients Starting on NovoMix® 30 Treatment
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2017-01-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 509
- Registration Number
- NCT00696995
- Locations
- 🇫🇮
Novo Nordisk Investigational Site, Lahti, Finland
A Randomised Controlled Clinical Trial in Type 2 Diabetes Comparing Semaglutide to Placebo and Liraglutide
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-06-13
- Last Posted Date
- 2019-08-14
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 415
- Registration Number
- NCT00696657
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Trowbridge, United Kingdom
Observational Study to Assess the Quality of Life and Clinical Outcomes in Subjects Using NovoMix® 30 for the Treatment of Diabetes
- First Posted Date
- 2008-06-12
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24975
- Registration Number
- NCT00696163
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Bangalore, India
Observational Study of Glycaemic Control in Patients Uncontrolled on Oral Antidiabetic Agents and Starting With 1 (Once) Daily Levemir® (Insulin Detemir) as the Treatment of Type 2 Diabetes Mellitus
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2016-10-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 2188
- Registration Number
- NCT00687284
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Kosice, Slovakia
Observational Study of Safety and Efficacy of Levemir® in Type 2 Diabetes
- First Posted Date
- 2008-05-30
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 10008
- Registration Number
- NCT00687063
Observational Study on Blood Glucose Control in Patients With Diabetes Using Modern Insulin
Completed
- Conditions
- Interventions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2016-10-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 3809
- Registration Number
- NCT00676741
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Bratislava, Slovakia
Comparison of the Pharmacodynamics and Pharmacokinetics of Insulin Aspart and Human Insulin in Elderly People With Type 2 Diabetes
Phase 4
Completed
- Conditions
- First Posted Date
- 2008-05-13
- Last Posted Date
- 2017-03-16
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 19
- Registration Number
- NCT00676819
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Köln, Germany
© Copyright 2024. All Rights Reserved by MedPath